title: Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy.
abstract: OBJECTIVE
  We present a technique that fuses pelvic CT scans and ProstaScint images to localize areas of disease within the prostate gland to customize prostate implants. Additionally, the acute toxicity results from the first 43 patients treated with this technique are reviewed.
  
  
  METHODS
  Between 2/97 and 8/98, 43 patients with clinical stage II prostate adenocarcinoma received ultrasound-guided transperineal implantation of I-125 or Pd-103 seeds. The median patient age was 70 years (range 49-79). Prior to treatment, the median Gleason score and prostate-specific antigen (PSA) were 6 (range 3-8) and 7.5 (range 1.8-16.6 ng/mL), respectively. The median follow-up was 10 months (range 2.9-20.4 months).
  
  
  RESULTS
  The median PSA value at 10 months is 0.7 ng/mL. Significant acute complications within the first month following implantation included 13 Grade I urinary symptoms, 24 Grade II urinary symptoms, 6 Grade III symptoms, and no Grade IV complications. Beyond 4 months, complications included 12 Grade I urinary symptoms, 17 Grade II urinary symptoms, 1 Grade III, and 1 Grade IV complications.
  
  
  CONCLUSIONS
  The image fusion of the pelvic CT scan and ProstaScint scans helped identify regions within the prostate at high risk of local failure, which were targeted with additional seeds during implantation.
authors.affiliation: Department of Radiation Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA. rod.ellis@uhhs.com
authors.forename: R J
authors.initials: RJ
authors.lastname: Ellis
authors.forename: D B
authors.initials: DB
authors.lastname: Sodee
authors.forename: J P
authors.initials: JP
authors.lastname: Spirnak
authors.forename: K H
authors.initials: KH
authors.lastname: Dinchman
authors.forename: A W
authors.initials: AW
authors.lastname: O'Leary
authors.forename: M A
authors.initials: MA
authors.lastname: Samuels
authors.forename: M I
authors.initials: MI
authors.lastname: Resnick
authors.forename: T J
authors.initials: TJ
authors.lastname: Kinsella
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D000368:Aged; D000911:Antibodies, Monoclonal; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D011877:Radionuclide Imaging; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014555:Urination Disorders / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; C101315:Capromab Pendetide; D017430:Prostate-Specific Antigen